Xth Eurasian Hematology-Oncology Congress

http://www.ehog.net/

 

Xth Eurasian Hematology-Oncology Congress
Z

2019 Update on Neoadjuvant Treatment of Melanoma: Immunotherapy Provides Better Outcome Than Targeted Therapy in Partial Response Patients and Better RFS

By Xth Eurasian Hematology-Oncology Congress FEATURING Zeynep Turna
By Xth Eurasian Hematology-Oncology Congress FEATURING Zeynep Turna
0 views
December 4, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

23:35
University of Colorado Division of Hematology

2024 Updates in PV/ET

Feat. B. McMahon

Featured Video

11:12
Stemline

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba
Skin
14:32
Xth Eurasian Hematology-Oncology Congress

2019 Update on Adjuvant Treatment of Melanoma: CPIs and BRAF MEK Are…

Feat. Z. Turna
06:35
Xth Eurasian Hematology-Oncology Congress

2019 Update on Neoadjuvant Treatment of Melanoma: Immunotherapy Prov…

Feat. Z. Turna
21:19
Xth Eurasian Hematology-Oncology Congress

Markers for Immune Checkpoint Inhibitor Resistance in Skin Cancer: M…

Feat. S. Seber
05:25
Xth Eurasian Hematology-Oncology Congress

The Evolution of Metastatic Melanoma Treatment: Does PD-L1 Status Al…

Feat. D. Erdem
15:44
Xth Eurasian Hematology-Oncology Congress

Metastatic BRAF+ Melanoma Treatment: Do We Sequence or Combine IO w/…

Feat. D. Erdem